Literature DB >> 15183112

Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines.

Thomas Efferth1, Franz Oesch.   

Abstract

The antimalarial artemisinins also reveal profound cytotoxic activity against tumor cells. Artemisinins harbor an endoperoxide bridge whose cleavage results in the generation of reactive oxygen species (ROS) and/or artemisinin carbon-centered free radicals. Established cancer drugs such as anthracyclines also form ROS and free radicals that are responsible for the cardiotoxicity of anthracyclines. In contrast, artemisinins do not reveal cardiotoxicity. In the present investigation, we compared the cytotoxic activities of different artemisinins (artemisinin, artesunate, arteether, artemether, artemisitene, dihydroartemisinylester stereoisomers) in 60 cell lines of the National Cancer Institute (NCI), USA, with those of anthracyclines (doxorubicin, daunorubicin, 4'-epirubicin, idarubicin, deoxydoxorubicin, trifluoroacetyl-doxorubicin-14-valerate). The inhibition concentration 50% (IC(50)) values of artemisinins and anthracyclines were correlated with the mRNA expression of 170 genes involved in oxygen stress response and metabolism as recently determined by microarray analysis and deposited in the NCI database (http://dtp.nci.nih.gov). The genes whose expression was significantly linked to cellular drug response in Kendall's tau tests were subjected to hierarchical cluster analysis and cluster image mapping. Mathematical correction for false-positive correlations was done by a false discovery rate algorithm. One cluster contained predominantly genes with a relationship to artemisinins and another one genes with a relationship to anthracyclines. In a third cluster, genes correlating to both drug classes were assembled. This indicates that different sets of genes involved in oxidative stress response and metabolism may contribute to the cytotoxic and differing toxic side effects of these drug classes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183112     DOI: 10.1016/j.bcp.2004.03.003

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  22 in total

1.  Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells.

Authors:  Kris G Hargraves; Lin He; Gary L Firestone
Journal:  Mol Carcinog       Date:  2015-03-19       Impact factor: 4.784

Review 2.  Development of artemisinin compounds for cancer treatment.

Authors:  Henry C Lai; Narendra P Singh; Tomikazu Sasaki
Journal:  Invest New Drugs       Date:  2012-08-31       Impact factor: 3.850

3.  The effects of intralaboratory modifications to media composition and cell source on the expression of pharmaceutically relevant transporters and metabolizing genes in the Caco-2 cell line.

Authors:  Wyatt J Roth; David J Lindley; Stephen M Carl; Gregory T Knipp
Journal:  J Pharm Sci       Date:  2012-07-11       Impact factor: 3.534

4.  The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells.

Authors:  Jin-Jian Lu; Si-Meng Chen; Xiao-Wei Zhang; Jian Ding; Ling-Hua Meng
Journal:  Invest New Drugs       Date:  2010-07-07       Impact factor: 3.850

5.  Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cells.

Authors:  V Badireenath Konkimalla; Martina Blunder; Bernhard Korn; Shahid A Soomro; Herwig Jansen; Wonsuk Chang; Gary H Posner; Rudolf Bauer; Thomas Efferth
Journal:  Nitric Oxide       Date:  2008-04-22       Impact factor: 4.427

6.  Activation of artemisinin and heme degradation in Leishmania tarentolae promastigotes: A possible link.

Authors:  Gerald Geroldinger; Matthias Tonner; Judith Quirgst; Martin Walter; Sritama De Sarkar; Laura Machín; Lianet Monzote; Klaus Stolze; J Catharina Duvigneau; Katrin Staniek; Mitali Chatterjee; Lars Gille
Journal:  Biochem Pharmacol       Date:  2019-11-29       Impact factor: 5.858

7.  Antimalarial Drug Artemether Inhibits Neuroinflammation in BV2 Microglia Through Nrf2-Dependent Mechanisms.

Authors:  Uchechukwu P Okorji; Ravikanth Velagapudi; Abdelmeneim El-Bakoush; Bernd L Fiebich; Olumayokun A Olajide
Journal:  Mol Neurobiol       Date:  2015-11-25       Impact factor: 5.590

8.  Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells.

Authors:  Beatrice Bachmeier; Iduna Fichtner; Peter H Killian; Emanuel Kronski; Ulrich Pfeffer; Thomas Efferth
Journal:  PLoS One       Date:  2011-05-26       Impact factor: 3.240

Review 9.  Artemisinins: their growing importance in medicine.

Authors:  Sanjeev Krishna; Leyla Bustamante; Richard K Haynes; Henry M Staines
Journal:  Trends Pharmacol Sci       Date:  2008-08-25       Impact factor: 14.819

Review 10.  A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Authors:  Richard E Kast; John A Boockvar; Ansgar Brüning; Francesco Cappello; Wen-Wei Chang; Boris Cvek; Q Ping Dou; Alfonso Duenas-Gonzalez; Thomas Efferth; Daniele Focosi; Seyed H Ghaffari; Georg Karpel-Massler; Kirsi Ketola; Alireza Khoshnevisan; Daniel Keizman; Nicolas Magné; Christine Marosi; Kerrie McDonald; Miguel Muñoz; Ameya Paranjpe; Mohammad H Pourgholami; Iacopo Sardi; Avishay Sella; Kalkunte S Srivenugopal; Marco Tuccori; Weiguang Wang; Christian R Wirtz; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.